目的:分析EPCR-PAR1抗炎通路与肾透明细胞癌(renal clear cell carcinoma,KIRC)的关系,进行深入全面的生物学分析,探索KIRC的新治疗靶点。方法:系统分析来自肿瘤基因组图谱数据库(the cancer genome atlas,TCGA)的KIRC癌组织和正常组织样本中EPCR-PAR1通路8个抗炎基因的表达,采用LASSO回归、COX回归构建预后指数,分析EPCR-PAR1通路相关抗炎基因表达与KIRC患者预后的关联。结果:本研究构建了一个包含5个基因的风险评分模型(Risk score=0.100 82×F3+0.046 40×PROC-0.353 21×vWF+0.152 82×CAV1+0.180 69×GRK5),通过时间依赖性ROC曲线分析模型的预测能力,结合Risk score和临床因素构建的预后模型具有良好的预测性能。将相关临床病理特征和风险评分进行单变量和多变量Cox回归分析发现,风险评分(HR=3.2,95% CI=1.9-5.6,P＜0.000 1)是肾透明细胞癌的独立危险因素。结论:EPCR-PAR1抗炎通路中这8个基因可作为KIRC预后的辅助标志物。
[1] Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update[J]. Eur Urol, 2015, 67(5): 913-924.
[2] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[3] Cui H, Shan H, Miao MZ, et al. Identification of the key genes and pathways involved in the tumorigenesis and prognosis of kidney renal clear cell carcinoma[J]. Sci Rep, 2020, 10(1): 4271.
[4] Lohse CM, Cheville JC. A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma[J]. Clin Lab Med, 2005, 25(2): 433-464.
[5] Golshayan AR, George S, Heng DY, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy[J]. J Clin Oncol, 2009, 27(2): 235-241.
[6] Schutz FA, Xie W, Donskov F, et al. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium[J]. Euro Urol, 2014, 65(4): 723-730.
[7] Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation[J]. Nature, 2008, 454(7203): 436-444.
[8] Bryant T. Remarks on some cases of inflammation of the breast simulating cancer[J]. Br Med J, 1868, 2(415): 608-609.
[9] Waldner MJ, Neurath MF. Colitis-associated cancer: the role of T cells in tumor development[J]. Sem Immunopathol, 2009, 31(2): 249-256.
[10] Murata M. Inflammation and cancer[J]. Environ Health Prev Med, 2018, 23(1): 50.
[11] Kondreddy V, Wang J, Keshava S, et al. Factor VIIa induces anti-inflammatory signaling via EPCR and PAR1[J]. Blood, 2018, 131(21): 2379-2392.
[12] Mitsui S, Oe Y, Sekimoto A, et al. Dual blockade of protease-activated receptor 1 and 2 additively ameliorates diabetic kidney disease[J]. Am J Physiol Renal Physiol, 2020, 318(5): F1067-1073.
[13] Mohan Rao LV, Esmon CT, Pendurthi UR. Endothelial cell protein C receptor: a multiliganded and multifunctional receptor[J]. Blood, 2014, 124(10): 1553-1562.
[14] Pendurthi UR, Rao LVM. Endothelial cell protein C receptor-dependent signaling[J]. Curr Opin Hematol, 2018, 25(3): 219-226.
[15] Pang L, Li JF, Su L, et al. ALEX1,a novel tumor suppressor gene,inhibits gastric cancer metastasis via the PAR-1/Rho GTPase signaling pathway[J]. J Gastroenterol, 2018, 53(1): 71-83.
[16] Han N, Li H, Wang H. MicroRNA-203 inhibits epithelial-mesenchymal transition, migration, and invasion of renal cell carcinoma cells via the inactivation of the PI3K/AKT signaling pathway by inhibiting CAV1[J]. Cell Adh Migr, 2020, 14(1): 227-241.
[17] Zhao TL, Gan XX, Bao Y, et al. GRK5 promotes tumor progression in renal cell carcinoma[J]. Neoplasma, 2019, 66(2): 261-70.
[18] Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1): W98-102.
[19] Cao D, Qu Y, Zhang X, et al. High expression of F2RL3 correlates with aggressive features and poor survival in clear cell renal cell carcinoma[J]. J Cancer, 2018, 9(18): 3400-3406.
[20] Weinstein JN, Collisson EA, Mills GB, et al. The cancer genome atlas pan-cancer analysis project[J]. Nature Genetics, 2013, 45(10): 1113-1120.
[21] Goldman M, Craft B,Swatloski T,et al.The UCSC cancer genomics browser: update 2015[J]. Nucleic Acids Res, 2015, 43(Database issue): 812-817.
[22] Uhlén M, Fagerberg L,Hallström BM, et al. Proteomics tissue-based map of the human proteome[J]. Science (New York, NY), 2015, 347(6220): 1260419.
[23] Bazzi WM, Sjoberg DD, Feuerstein MA, et al. Long-term survival rates after resection for locally advanced kidney cancer: memorial sloan kettering cancer center 1989 to 2012 experience[J]. J Urol, 2015, 193(6): 1911-1916.
[24] Li P, Wong YN, Armstrong K, et al. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras[J]. Cancer Med, 2016, 5(2): 169-181.
[25] Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging[J]. CA Cancer J Clin 2017, 67(2): 93-99.
[26] Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM[J]. Ann Surg Oncol, 2010, 17(6): 1471-1474.
[27] Kim SP, Alt AL, Weight CJ, et al. Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort[J]. J Urol, 2011, 185(6): 2035-2039.
[28] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-386.
[29] Baco E, Rud E, Eri LM, et al. A randomized controlled trial to assess and compare the outcomes of two-core prostate biopsy guided by fused magnetic resonance and transrectal ultrasound images and traditional 12-core systematic biopsy[J]. Eur Urol, 2016, 69(1): 149-156.
[30] Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets[J]. Nucleic Acids Res, 2019, 47(D1): D607-613.
